Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

27 Oct, 2011, 04:28 ET from Reportlinker

NEW YORK, Oct. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

http://www.reportlinker.com/p0661233/Polycystic-Ovarian-Syndrome-PCOS-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, "Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global PCOS market. The report identifies the key trends shaping and driving the global PCOS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global PCOS sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

GlobalData estimates that the global PCOS therapeutics market was valued at $656m in 2010, and is expected to grow at a static Compound Annual Growth Rate (CAGR) of 2.6% over the next eight years, to reach $804m by 2018. The growing treated population which is mainly due to expanding prevalence of co-morbid conditions such as diabetes, obesity and dyslipidemia will drive steady growth in PCOS therapeutics market. Although treated patients are increasing but the market is showing static growth because of the unavailability of FDA approved and presence of off-label and generic products for treatment which are having lower patient satisfaction due to lower efficacy profiles since these products can not treat all the conditions such as hyperandrogenism, infertility, hyperglycemia and hirsutism, associated with PCOS. So still a huge unmet need exists in the management of treatment pattern with the help of more efficacious products which can cure all the conditions. In the pipeline of PCOS, majority of the participants are institutions or universities. Company participation is very low because most of the drugs which are under trial are generics and already being used for this indication either alone or in combination. Therefore current pipeline products are not going to impact the market significantly.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the PCOS market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) PCOS market revenues data from 2005 to 2010, forecast for eight years to 2018.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Antiplatelate action, Ovulation inducer, Hypoglycemic, Antiandrogen, Progesterone derivative, Oral contraceptives, Antiobesity drugs and others.

- Analysis of the current and future competition in the global PCOS market. Key market player covered is Reliance Life Sciences Pvt. Ltd.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the PCOS therapeutics market.

- Analysis of key recent licensing and partnership agreements in PCOS market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global PCOS market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global PCOS market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global PCOS market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 6

1.2 List of Figures 6

2 Polycystic Ovarian Syndrome (PCOS) Therapeutics: Executive Summary 8

2.1 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market is Forecast to Show Significant Growth until 2018 8

2.2 Need for FDA approved products 9

2.3 Weak pipeline with no disease modifying therapies 10

3 Polycystic Ovarian Syndrome (PCOS) Therapeutics: Introduction 11

3.1 Disease Overview 11

3.2 Epidemiology 11

3.3 Etiology and Pathology 14

3.3.1 Androgen Excess 15

3.3.2 Ovulatory Dysfunction 16

3.3.3 Insulin Resistance 16

3.3.4 Obesity and Adipose Tissue Dysfunction 16

3.3.5 Gonadotropin Abnormalities 16

3.3.6 Intrauterine Environment 16

3.3.7 Infancy to Adolescence 16

3.3.8 Genetics 17

3.3.9 Environmental Factors 17

3.4 Signs and Symptoms 18

3.5 Diagnosis 18

3.5.1 Careful History and Physical Examination 18

3.5.2 Laboratory Examination 18

3.6 Treatment and Management Pattern 19

3.6.1 Patient and Family Education 20

3.6.2 Non-Pharmacological Treatment 21

3.6.3 Pharmacological Treatment 21

3.7 Referral Pathway 22

3.8 GlobalData Pipeline Report Guidance 22

4 PCOS Therapeutics: Market Characterization 24

4.1 PCOS Therapeutics Market Size (2005–2010) – Global 24

4.2 PCOS Therapeutics Market Forecast (2010–2018) – Global 25

4.3 PCOS Therapeutics Market Size (2005–2010) – The US 26

4.4 PCOS Therapeutics Market Forecast (2010–2018) – The US 27

4.5 PCOS Therapeutics Market Size (2005–2010) – France 28

4.6 PCOS Therapeutics Market Forecast (2010–2018) – France 29

4.7 PCOS Therapeutics Market Size (2005–2010) – Germany 31

4.8 PCOS Therapeutics Market Forecast (2010–2018) – Germany 32

4.9 PCOS Therapeutics Market Size (2005–2010) – Italy 33

4.10 PCOS Therapeutics Market Forecast (2010–2018) – Italy 34

4.11 PCOS Therapeutics Market Size (2005–2010) – Spain 35

4.12 PCOS Therapeutics Market Forecast (2010–2018) – Spain 36

4.13 PCOS Therapeutics Market Size (2005–2010) – The UK 37

4.14 PCOS Therapeutics Market Forecast (2010–2018) – The UK 38

4.15 PCOS Therapeutics Market Size (2005–2010) – Japan 40

4.16 PCOS Therapeutics Market Forecast (2010–2018) – Japan 41

4.17 Drivers and Barriers for the PCOS therapeutics market 42

4.17.1 Drivers for the PCOS therapeutics market 42

4.17.2 Barriers for the PCOS therapeutics market 42

4.17.3 Opportunity and Unmet need analysis 43

4.18 Key Takeaway 44

5 PCOS Therapeutics: Competitive Assessment 46

5.1 Overview 46

5.2 Strategic Competitor Assessment 46

5.3 Product Profiles for the Major Products in the PCOS Therapeutics Market 47

5.3.1 Oral contraceptives 47

5.3.2 Long-acting Gonadotropin-Releasing Hormone (GnRH) analogues 49

5.3.3 Insulin sensitising agents 50

5.3.4 Ovulation inducer 51

5.3.5 Antiandrogens/ Hirsutism treatment 52

Spiranolactone 52

5.4 Key Takeaway 53

6 PCOS Therapeutics: Pipeline Assessment 54

6.1 Overview 54

6.2 Strategic Pipeline Assessment 54

6.3 PCOS Therapeutics Pipeline – Pipeline by Phase of Development 55

6.3.1 PCOS Therapeutics – Phase III Pipeline 55

6.3.2 PCOS Therapeutics – Phase II/III Pipeline 56

6.3.3 PCOS Therapeutics – Phase II Pipeline 56

6.3.4 PCOS Therapeutics – Phase I/II Pipeline 56

6.3.5 Technology Trends Analytic Framework 56

6.4 PCOS Therapeutics Market –Pipeline by Mechanism of Action 58

6.5 PCOS Therapeutics – Promising Drugs under Clinical Development 60

6.6 Molecule Profile for Promising Drugs under Clinical Development 60

6.6.1 R-TPR-020 60

6.7 Key Takeaway 60

7 PCOS Therapeutics: Clinical Trials Mapping 61

7.1 Clinical Trials by Region/Country (US, EU5 and Japan) 61

7.2 Clinical Trials by Phase 62

7.3 Clinical Trials by Trial Status 63

7.4 Prominent Sponsors 64

7.5 Top Companies Participating in PCOS Therapeutics Clinical Trials 66

8 Strategic Assessment 67

8.1 Key Events Impacting the Future Market 67

8.2 PCOS Therapeutics: Implications for Future Market Competition 68

9 PCOS Therapeutics: Future Players 70

9.1 Introduction 70

9.2 Company Profiles 71

9.2.1 Reliance Life Sciences Pvt. Ltd. 71

10 PCOS Therapeutics: Licensing and Partnership Deals 72

11 PCOS Therapeutics: Appendix 73

11.1 Market Definitions 73

11.2 Abbreviations 73

11.3 Research Methodology 74

11.3.1 Coverage 75

11.3.2 Secondary Research 75

11.3.3 Forecasting 75

11.3.4 Primary Research 77

11.3.5 Expert Panel Validation 78

11.4 Contact Us 78

11.5 Disclaimer 78

11.6 Bibliography 78

List of Tables

Table 1: Diagnostic Criteria for PCOS 11

Table 2: Common Comorbidity associated with PCOS 12

Table 3: Prevalence by Country 14

Table 4: Laboratory Tests for the Evaluation of Patients with Suspected PCOS 19

Table 5: Commonly used Off-label Drugs 21

Table 6: PCOS Therapeutics Market, Global, Revenue ($m), 2005–2010 25

Table 7: PCOS Therapeutics Market, Global, Forecast ($m), 2010–2018 26

Table 8: PCOS Therapeutics Market, the US, Revenue ($m), 2005–2010 27

Table 9: PCOS Therapeutics Market, the US, Forecasts ($m), 2010–2018 28

Table 10: PCOS Therapeutics Market, France, Revenue ($m), 2005–2010 29

Table 11: PCOS Therapeutics Market, France, Forecasts ($m), 2010–2018 30

Table 12: PCOS Therapeutics Market, Germany, Revenue ($m), 2005–2010 31

Table 13: PCOS Therapeutics Market, Germany, Forecasts ($m), 2010–2018 33

Table 14: PCOS Therapeutics Market, Italy, Revenue ($m), 2005–2010 34

Table 15: PCOS Therapeutics Market, Italy, Forecasts ($m), 2010–2018 35

Table 16: PCOS Therapeutics Market, Spain, Revenue ($m), 2005–2010 36

Table 17: PCOS Therapeutics Market, Spain, Forecasts ($m), 2010–2018 37

Table 18: PCOS Therapeutics Market, the UK, Revenue ($m), 2005–2010 38

Table 19: PCOS Therapeutics Market, the UK, Forecasts ($m), 2010–2018 39

Table 20: PCOS Therapeutics Market, Japan, Revenue ($m), 2005–2010 40

Table 21: PCOS Therapeutics Market, Japan, Forecasts ($m), 2010–2018 42

Table 22: PCOS Therapeutics, Phase III Pipeline, 2011 55

Table 23: PCOS Therapeutics, Phase II/III Pipeline, 2011 56

Table 24: PCOS Therapeutics, Phase II Pipeline, 2011 56

Table 25: PCOS Therapeutics, Phase I/II Pipeline, 2011 56

Table 26: PCOS Therapeutics – Most Promising Drugs under Clinical Development, 2011 60

Table 27: PCOS Therapeutics, Clinical Trials by Country, 2011 61

Table 28: PCOS Therapeutics - Clinical Trials by Phase, 2011 62

Table 29: PCOS Therapeutics, Clinical Trials by Status, 2011 63

Table 30: PCOS Therapeutics, Prominent Sponsors, 2011 66

Table 31: PCOS Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 66

Table 32: Reliance Life Sciences Pvt. Ltd., PCOS Management, Pipeline, 2011 71

List of Figures

Figure 1: PCOS Therapeutics Market, Global, Revenue and Forecasts ($m), 2005–2018 9

Figure 2: Opportunity and Unmet Need in the PCOS Therapeutics Market, 2011 10

Figure 3: Common Comorbidities Associated with PCOS 12

Figure 4: Annual Burden with the Treatment of PCOS in 2004 13

Figure 5: Pathophysiology of PCOS 15

Figure 6: Signs and Symptoms 18

Figure 7: PCOS: Treatment Algorithm 20

Figure 8: Referral Pathway 22

Figure 9: PCOS Therapeutics Market, Global, Revenue ($m), 2005–2010 24

Figure 10: PCOS Therapeutics Market, Global, Forecast ($m), 2010–2018 26

Figure 11: PCOS Therapeutics Market, the US, Forecast ($m), 2005–2010 27

Figure 12: PCOS Therapeutics Market, the US, Forecast ($m), 2010–2018 28

Figure 13: PCOS Therapeutics Market, France, Revenue ($m), 2005–2010 29

Figure 14: PCOS Therapeutics Market, France, Forecast ($m), 2010–2018 30

Figure 15: PCOS Therapeutics Market, Germany, Revenue ($m), 2005–2010 31

Figure 16: PCOS Therapeutics Market, Germany, Forecast ($m), 2010–2018 32

Figure 17: PCOS Therapeutics Market, Italy, Revenue ($m), 2005–2010 33

Figure 18: PCOS Therapeutics Market, Italy, Forecast ($m), 2010–2018 35

Figure 19: PCOS Therapeutics Market, Spain, Revenue ($m), 2005–2010 36

Figure 20: PCOS Therapeutics Market, Spain, Forecast ($m), 2010–2018 37

Figure 21: PCOS Therapeutics Market, the UK, Revenue ($m), 2005–2010 38

Figure 22: PCOS Therapeutics Market, the UK, Forecast ($m), 2010–2018 39

Figure 23: PCOS Therapeutics Market, Japan, Revenue ($m), 2005–2010 40

Figure 24: PCOS Therapeutics Market, Japan, Forecast ($m), 2010–2018 41

Figure 25: Opportunity and Unmet Need in the PCOS Therapeutics Market, 2011 44

Figure 26: PCOS Therapeutics, Strategic Competitor Assessment, 2010 47

Figure 27: PCOS Therapeutics – Pipeline by Phase of Development, 2011 55

Figure 28: PCOS Therapeutics, Technology Trends Analytics Framework, 2011 57

Figure 29: PCOS Pipeline, Technology Trends Analytics Framework, Description, 2011 58

Figure 30: PCOS Therapeutics, Pipeline by Mechanism of Action, 2011 59

Figure 31: PCOS Therapeutics, Clinical Trials by Country, 2011 61

Figure 32: PCOS Therapeutics, Clinical Trials by Phase (%), 2011 62

Figure 33: PCOS Therapeutics, Clinical Trials by Status (%), 2011 63

Figure 34: PCOS Therapeutics, Overall Sponsors (%), 2011 64

Figure 35: PCOS Therapeutics, Prominent Sponsors (%), 2011 65

Figure 36: PCOS Therapeutics Market, Drivers and Restraints, 2011 67

Figure 37: Implications for Future Market Competition in the PCOS Market, 2011 68

Figure 38: PCOS Therapeutics Market, Pipeline by Company, 2011 70Reliance Life Sciences Pvt. Ltd.

To order this report:

Pathology Industry: Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Pathology Business News

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com